MedTrace Logo

Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

NCT05821387 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-08-29

No results posted yet for this study

Summary

This study aims to determine the safety, tolerability, and pharmacokinetics of single doses of Lucid-21-302 in healthy adult volunteers. This study will also investigate the effects of food in healthy volunteers.

Conditions

  • Healthy Participants

Interventions

DRUG

Lucid-21-302

A small molecule inhibitor of hypercitrullination

DRUG

Placebo

Product containing excipients with no active ingredients

Sponsors & Collaborators

  • Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)

    collaborator UNKNOWN

  • Quantum Biopharma

    lead INDUSTRY

Principal Investigators

  • Isabella Szeto, MD · Biopharma Services Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2023-07-29
Completion
2023-07-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821387 on ClinicalTrials.gov